20 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
offerings. We expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. The Company reviews acquired R&D … and licenses to determine if they should be capitalized or expensed under U.S. GAAP standards.
Below is a disaggregation of R&D expenses
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
offerings. We expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. The Company reviews acquired R&D … and licenses to determine if they should be capitalized or expensed under U.S. GAAP standards.
Below is a disaggregation of R&D expenses
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
such costs qualify for capitalization under applicable guidance. The Company reviews acquired R&D and licenses to determine if they should … be capitalized or expensed under U.S. GAAP standards.
Below is a disaggregation of R&D expenses:
For the Three Months Ended
March 31, 2024
March 31, 2023
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
and strategy
We are an R&D stage pharmaceutical company, with no commercial operations or revenue streams. Since our IPO, our sole business activity has been … expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. The Company reviews acquired R&D and licenses
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
and strategy
We are an R&D stage pharmaceutical company, with no commercial operations or revenue streams. Since our IPO, our sole business activity has been … expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. The Company reviews acquired R&D and licenses
10-K
wg5x1eka
16 Apr 24
Annual report
4:48pm
424B4
3x8t8m3ti9i3kpk
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
ujs1nqx
20 Feb 24
Prospectus supplement with pricing info
5:28pm
DRS/A
i1jmamw8jcvjq4du5p
17 Oct 22
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next